Looking AheadOptimizing Management Strategies in Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis Overview and Pathogenesis
Ardern-Jones MR, et al. Proc Natl Acad Sci U S A. 2007;104(13):5557-5562.
Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971.
Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574.
Patient Burden and Comorbidities
Burgess JA, et al. J Allergy Clin Immunol. 2008;122(2):280-285.
Chamlin SL, et at. Arch Pediatr Adolesc Med. 2005;159(8):745-750.
Mitchell AE. Psychol Res Behav Manag. 2018;11:289-298.
Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis.
Simpson EL, et al. JAMA Dermatol. 2018;154(8):903-912.
Yaghmaie P, et al. J Allergy Clin Immunol. 2013;131(2):428-433.
Management of Atopic Dermatitis
Ariëns LFM, et al Ther Adv Chronic Dis. 2018;9(9):159-170.
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.
Bakker DS, et al. Br J Dermatol. 2019;180(5):1248-1249.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.
Boguniewicz M, et al. Ann Allergy Asthma Immunol. 2018;120(1):10-22.
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.
Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.
Huang JT, et al. Pediatrics. 2009;123(5):e808-e814.
Ruzicka T, et al. N Engl J Med. 2017;376(9):826-835.
Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.
Clinical Insights Into Atopic Dermatitis Pathogenesis
This short video discusses the pathophysiology of atopic dermatitis, illustrating how it is a disease of both barrier dysfunction and Th2-driven inflammation. Among Th2 cytokines, IL-4 and IL-13 have demonstrated a key role in AD pathogenesis, which has led to the development of a human monoclonal antibody against IL-4Rα for the treatment of moderate-to-severe disease.
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Improving Outcomes for Patients with COPD
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A New Era in Precision Medicine
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
New Strategies to Target Remission and Individualize Comprehensive Care
Targeting Immune Dysregulation and Delivering Comprehensive Care
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
Looking Beyond Barriers to Optimize Therapy
Debates and Discussions About Personalizing Patient Management
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
From Guideline Recommendations to Daily Clinical Decision-Making
Improving Patient Outcomes Through Shared Clinical Decision Making
Debates and Discussions About Pustular Disease Subtypes
Collaborative Care for Better Patient Outcomes
Interdisciplinary Management of Patients With Severe Asthma